Generation of Novel Anti-MUC1 Monoclonal Antibodies with Designed Carbohydrate Specificities Using MUC1 Glycopeptide Library
Author(s) -
Shoichi Naito,
Tatsuya Takahashi,
Junji Onoda,
Shoko Uemura,
Naoki Ohyabu,
Hiroshi Takemoto,
Shoji Yamane,
Ikuo Fujii,
ShinIchiro Nishimura,
Yoshito Numata
Publication year - 2017
Publication title -
acs omega
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.779
H-Index - 40
ISSN - 2470-1343
DOI - 10.1021/acsomega.7b00708
Subject(s) - glycan , epitope , muc1 , monoclonal antibody , glycopeptide , glycosylation , antibody , chemistry , glycoprotein , mucin , biochemistry , microbiology and biotechnology , biology , immunology , antibiotics
Numerous anti-mucin 1 (anti-MUC1) antibodies that recognize O -glycan core structures have already been developed. However, most of them show low specificities toward O -glycan structures and/or low affinity toward a monovalent epitope. In this study, using an MUC1 glycopeptide library, we established two novel anti-MUC1 monoclonal antibodies (1B2 and 12D10) with designed carbohydrate specificities. Compared with previously reported anti-MUC1 antibodies, 1B2 and 12D10 showed quite different features regarding their specificities, affinities, and reactivity profiles to various cell lines. Both antibodies recognized specific O -glycan structures at the PDT*R motif (the asterisk represents an O -glycosylation site). 1B2 recognized O -glycans with an unsubstituted O -6 position of the GalNAc residue (Tn, T, and 23ST), whereas 12D10 recognized Neu5Ac at the same position (STn, 26ST, and dST). Neither of them bound to glycopeptides with core 2 O -glycans that have GlcNAc at the O -6 position of the GalNAc residue. Furthermore, 1B2 and 12D10 showed a strong binding to not only native MUC1 but also 20-mer glycopeptide with a monovalent epitope. These anti-MUC1 antibodies should thus become powerful tools for biological studies on MUC1 O -glycan structures. Furthermore, the strategy of using glycopeptide libraries should enable the development of novel antibodies with predesigned O -glycan specificities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom